Summary of Risk-based Pneumococcal Vaccination Recommendations

Key points

  • CDC recommends pneumococcal vaccination for children and adults at increased risk for pneumococcal disease.
  • Follow the recommended immunization schedule to ensure that your patients get the pneumococcal vaccines that they need.
  • Find resources below, like CDC's free app, to help you implement pneumococcal vaccine recommendations.
Healthcare provider is using stethoscope to check patient.

App available to interpret recommendations

CDC offers PneumoRecs VaxAdvisor as a free app to quickly and easily provide patient-specific pneumococcal vaccine guidance. It's available for download for iOS and Android mobile devices. There's also a web-based version that doesn't require a download.

Children 2 through 5 years old

The following guidance applies to children in this age group who have a risk condition.

Unvaccinated or <3 PCV doses before age 2 years

Give 2 doses of PCV15 or PCV20. Give the second dose at least 8 weeks after the first.

Determine if they've ever received a dose of PCV20:

Received PCV20
  • Their pneumococcal vaccinations are complete.
Never received PCV20
  • See "Complete PCV series that didn't include PCV20" guidance below.

3 PCV doses before age 12 months but no booster dose at or after age 12 months

Give 1 dose of PCV15 or PCV20.

Determine if they've ever received a dose of PCV20:

Received PCV20

  • Their pneumococcal vaccinations are complete.
Never received PCV20
  • See "Complete PCV series that didn't include PCV20" guidance below.

Complete PCV series that included PCV20

Their pneumococcal vaccines are complete.

Complete PCV series that didn't include PCV20

Recommendations depend on if the child's risk condition is an immunocompromising condition.

Immunocompromising condition

Determine if they have ever received a dose of PPSV23:

Received PPSV23
  • Then no pneumococcal vaccines are recommended at this time.
  • Wait until at least 5 years have passed since they received their first PPSV23 dose.
  • Then give 1 dose of PCV20 or PPSV23. Regardless of vaccine used (PCV20 or PPSV23), their pneumococcal vaccinations are then complete.
Never received PPSV23
  • Give 1 dose of PCV20 or PPSV23 at least 8 weeks after the last PCV dose.
  • When PCV20 is used, their pneumococcal vaccinations are then complete.
  • When PPSV23 is used, they need another pneumococcal vaccine at least 5 years later. At that time, give 1 dose of PCV20 or PPSV23. Regardless of vaccine used (PCV20 or PPSV23), their pneumococcal vaccinations are then complete.

Not an immunocompromising condition

Determine if they have ever received a dose of PPSV23:

Received PPSV23
  • Their pneumococcal vaccinations are complete.
Never received PPSV23
  • Give 1 dose of PCV20 or PPSV23 at least 8 weeks after last PCV dose. Regardless of vaccine used (PCV20 or PPSV23), their pneumococcal vaccinations are then complete.

Children 6 through 18 years old

The following guidance applies to children in this age group who have a risk condition.

Never received PCV13, PCV15, or PCV20

Give 1 dose of PCV15 or PCV20 at least 8 weeks after the most recent pneumococcal vaccine dose. Give it regardless of whether the child has previously received PPSV23 or PCV7.

When PCV15 is used
  • It should be followed by a dose of PPSV23 if not previously given.
When PCV20 is used
  • It doesn't need to be followed by a dose of PPSV23. Their pneumococcal vaccinations are complete.

Received PCV13 or PCV15 before age 6 years, never received PCV20

Recommendations depend on if the child's risk condition is an immunocompromising condition.

Immunocompromising condition

Determine if they already received PPSV23:

Received PPSV23
  • Then no pneumococcal vaccines are recommended at this time.
  • Wait until at least 5 years have passed since they received their first PPSV23 dose.
  • Then give 1 dose of PCV20 or PPSV23. Regardless of vaccine used (PCV20 or PPSV23), their pneumococcal vaccinations are then complete.
Never received PPSV23
  • Give 1 dose of PCV20 or PPSV23 at least 8 weeks after the last PCV dose.
  • When PCV20 is used, their pneumococcal vaccinations are complete.
  • When PPSV23 is used, they need another pneumococcal vaccine at least 5 years later. At that time, give either 1 dose of PCV20 or PPSV23. Regardless of vaccine used (PCV20 or PPSV23), their pneumococcal vaccinations are then complete.

Not an immunocompromising condition

Determine if they already received PPSV23:

Received PPSV23
  • Their pneumococcal vaccinations are complete.
Never received PPSV23
  • Give 1 dose of PCV20 or PPSV23 at least 8 weeks after the most recent pneumococcal vaccine dose. Regardless of vaccine used (PCV20 or PPSV23), their pneumococcal vaccinations are then complete.

Adults 19 through 64 years old

The following guidance applies to adults younger than 65 years who have a risk condition.

Job Aid for Adult Recommendations‎

View complete pneumococcal vaccine schedules for adults based on prior vaccination history. Pages 2–4 provide illustrations of vaccine options to complete the recommended pneumococcal vaccines for adults 19–64 years old.

Serotype 4 background information

PCV21 contains eight new pneumococcal serotypes not included in PCV15, PCV20, or PPSV23. However, PCV21 doesn't contain certain pneumococcal serotypes (e.g., serotype 4) included in other pneumococcal vaccines.

Populations at risk

In certain adult populations in the Western United States with data (Alaska, Colorado, New Mexico, Navajo Nation, and Oregon), serotype 4 has caused high percentages (i.e., ≥30%) of invasive pneumococcal disease (IPD). CDC currently doesn't know if this is seen in other parts of the Western United States that don't routinely monitor IPD data.

Typically, individuals living within these geographic areas who develop serotype 4 IPD are adults aged <65 years with specific underlying conditions or risk factors such as:

  • Alcoholism
  • Chronic lung disease
  • Cigarette smoking
  • Homelessness
  • Injection drug use

Importantly, these individuals usually haven't received a PCV containing serotype 4.

Serotype 4 coverage and vaccine choice

In such populations, other recommended pneumococcal vaccines (e.g., PCV20 alone or both PCV15 and PPSV23) are expected to provide broader serotype coverage against locally circulating strains compared to PCV21 alone.

Never received any pneumococcal vaccineA

Give 1 dose of PCV15, PCV20, or PCV21:

When PCV15 is used
  • It should be followed by a dose of PPSV23 Bat least 1 year later. The minimum interval (8 weeks) can be considered in adults with an immunocompromising condition, cochlear implant, or cerebrospinal fluid leak. Their pneumococcal vaccinations are then complete.
When PCV20 or PCV21 is used
  • It doesn't need to be followed by a dose of PPSV23. Regardless of vaccine used (PCV20 or PPSV23), their pneumococcal vaccinations are complete.

Only received PPSV23

Give 1 dose of PCV15, PCV20, or PCV21 at least 1 year after the most recent PPSV23 vaccination. Regardless of which vaccine is used (PCV15, PCV20, or PCV21), an additional dose of PPSV23 isn't recommended. Their pneumococcal vaccinations are complete.

Only received PCV13

Recommendations depend on the person's risk condition.

Immunocompromising condition

Give 1 dose of PCV20, PCV21, or PPSV23:

When PCV20 or PCV21 is used
  • It should be given at least 1 year after PCV13.
  • When PCV20 or PCV21 is used, their pneumococcal vaccinations are then complete.
When PPSV23 is used
  • It should be given at least 8 weeks after PCV13.
  • When PPSV23 is used, they need another pneumococcal vaccine at least 5 years later. At that time, give either 1 dose of PCV20, PCV21, or PPSV23.
  • When PCV20 or PCV21 is used, their pneumococcal vaccinations are then complete.
  • When a second PPSV23 dose is used, no additional pneumococcal vaccines are recommended until at least age 65 years. Review pneumococcal vaccine recommendations again when the patient turns 65 years old.

Cerebrospinal fluid leak or cochlear implant

Give 1 dose of PCV20, PCV21, or PPSV23:

When PCV20 or PCV21 is used
  • It should be given at least 1 year after PCV13.
  • When PCV20 or PCV21 is used, their pneumococcal vaccinations are then complete.
When PPSV23 is used
  • It should be given at least 8 weeks after PCV13.
  • When PPSV23 is used, no additional pneumococcal vaccines are recommended until at least age 65 years. Review pneumococcal vaccine recommendations again when the patient turns 65 years old.

Other risk conditionC

Give 1 dose of PCV20, PCV21, or PPSV23:

When PCV20 or PCV21 is used
  • It should be given at least 1 year after PCV13.
  • When PCV20 or PCV21 is used, their pneumococcal vaccinations are then complete.
When PPSV23 is used
  • It should be given at least 1 year after PCV13.
  • When PPSV23 is used, no additional pneumococcal vaccines are recommended until at least age 65 years. Review pneumococcal vaccine recommendations again when the patient turns 65 years old.

Received PCV13 and 1 dose of PPSV23

Recommendations depend on the person's risk condition.

Immunocompromising condition

Give 1 dose of PCV20, PCV21, or PPSV23:

When PCV20 or PCV21 is used
  • It should be given at least 5 years after the last pneumococcal vaccine.
  • When PCV20 or PCV21 is used, their pneumococcal vaccinations are then complete.
When PPSV23 is used (second dose)
  • It should be given at least 8 weeks after PCV13 and 5 years after first PPSV23 dose. No additional pneumococcal vaccines are recommended until at least age 65 years. Review pneumococcal vaccine recommendations again when the patient turns 65 years old.

Cerebrospinal fluid leak or cochlear implant

Give 1 dose of PCV20 or PCV21 at least 5 years after the last pneumococcal vaccine. Regardless of which vaccine is used (PCV20 or PCV21), their pneumococcal vaccinations are then complete.

Note: A second dose of PPSV23 isn't recommended at this age for these patients. If PCV20 or PCV21 isn't administered, then review pneumococcal vaccine recommendations again when the patient turns 65 years old.

Other risk conditionC

No additional pneumococcal vaccines are recommended until at least age 65 years. Review pneumococcal vaccine recommendations again when the patient turns 65 years old.

Risk conditions

Children and adults

Many conditions are an indication for pneumococcal vaccination for both children and adults:

  • Cerebrospinal fluid leak
  • Chronic liver disease
  • Cochlear implant
  • An immunocompromising condition
  • Diabetes mellitus

The following are considered immunocompromising conditions in both children and adults:

  • Congenital or acquired asplenia, or splenic dysfunction
  • Congenital or acquired immunodeficiencyD
  • Diseases or conditions treated with immunosuppressive drugs or radiation therapyE
  • HIV infection
  • Sickle cell disease or other hemoglobinopathy

Children specifically

The following risk conditions are only an indication for pneumococcal vaccination of children:

  • Chronic heart disease
    • Particularly cyanotic congenital heart disease and cardiac failure
  • Chronic kidney disease, excluding maintenance dialysis or nephrotic syndrome
  • Chronic lung disease
    • Includes moderate persistent or severe persistent asthma
  • Maintenance dialysis or nephrotic syndrome

Adults specifically

The following risk conditions are only an indication for pneumococcal vaccination of adults:

  • Alcoholism or cigarette smoking
  • Chronic heart disease
    • Includes congestive heart failure and cardiomyopathies
    • Excludes hypertension
  • Chronic lung disease
    • Includes chronic obstructive pulmonary disease, emphysema, and asthma
  • Chronic renal failure or nephrotic syndrome
  1. Also applies to people who received PCV7 at any age and no other pneumococcal vaccines.
  2. If PPSV23 is not available, one dose of PCV20 or PCV21 may be given.
  3. e.g., alcoholism, chronic heart disease, chronic liver disease, chronic lung disease, cigarette smoking, diabetes mellitus
  4. Includes B-(humoral) or T-lymphocyte deficiency; complement deficiencies, particularly C1, C2, C3, and C4 deficiency; and phagocytic disorders (excluding chronic granulomatous disease)
  5. Includes Hodgkin disease, leukemia, lymphoma, malignant neoplasm, and solid organ transplant